Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | P2RX4 | Q99571 | 13/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13408829 | 0.89 | KDM4E (0.34) | MAPTSMN1; SMN2NPSR1P2RX4KDM4E | |
| SCHEMBL13408895 | 0.87 | POLB (0.38) | MAPTSMN1; SMN2NPSR1KDM4EMAPK1 | |
| SCHEMBL13408810 | 0.85 | MAPT (0.33) | MAPTSMN1; SMN2NPSR1P2RX4KDM4E | |
| SCHEMBL13408880 | 0.85 | GPR84 (0.37) | MAPTSMN1; SMN2NPSR1KDM4E | |
| SCHEMBL13445217 | 0.81 | — | — | |
| SCHEMBL13445091 | 0.79 | — | — | |
| SCHEMBL13408796 | 0.78 | PDE6D (0.35) | MAPTSMN1; SMN2NPSR1P2RX4KDM4E | |
| SCHEMBL13408733 | 0.76 | ALDH1A1 (0.34) | MAPTSMN1; SMN2NPSR1KDM4EMAPK1 | |
| SCHEMBL13408718 | 0.76 | P2RX4 (0.36) | SMN1; SMN2NPSR1P2RX4MAPK1P2RX1 | |
| SCHEMBL12144430 | 0.76 | MAPT (0.39) | MAPTSMN1; SMN2NPSR1KDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100096982-A1 | Novel organic electroluminescent compounds and organic electrouminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-04-22 | — | — | US | disclosed |
| US-20100096982-A1 | Novel organic electroluminescent compounds and organic electrouminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-04-22 | — | — | US | disclosed |
| EP-2161319-A2 | Benzo(c)phenanthrene derivatives and organic electroluminescent device using the same | Gracel Display Inc. (KR) | 2010-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100096982-A1 | Novel organic electroluminescent compounds and organic electrouminescent device using the same | OCIAD1, OR10J3, ORMDL3 | MAPT 3332/4885SMN1; SMN2 4528/4885NPSR1 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.